First patient included in ex vivo clinical trial for Imuno's BiTE targeting

20 September 2024

We are excited to share that the collaboration between Imunotx and VitroScan is advancing to the first patient included in ex vivo clinical trial for Imuno's peptide MHC targeting T cell engagers!

Our collaboration started last year, after being awarded a Eureka/Eurostars/RVO grant for our multidisciplinary HITS [High-throughput ImmunoTherapy Screening] project to establish a fast and robust pipeline measuring the efficacy of novel immunotherapy drugs. We are collaborating to generate near patient evidence to prep for efficient clinical stage testing.